Open AccessCognitive decline according to amyloid uptake in patients with poststroke cognitive impairment
Author(s) -
Bora Yoon,
Dong Won Yang,
Yun-Jeong Hong,
TaeWon Kim,
Seunghee Na,
SangMi Noh,
Hye Lim Park,
Bon D. Ku,
Young Soon Yang,
Hojin Choi,
JaeWon Jang,
Seongheon Kim,
Yerim Kim,
Yong-Soo Shim
Publication year - 2021
Publication title -
medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.59
H-Index - 148
eISSN - 1536-5964
pISSN - 0025-7974
DOI - 10.1097/md.0000000000027252
Subject(s) - medicine , dementia , clinical dementia rating , cognition , cognitive decline , observational study , mini–mental state examination , amyloid (mycology) , cerebral infarction , pathology , psychiatry , disease , ischemia
Background and purpose: Poststroke cognitive impairment (PSCI) is common, but the impact of β-amyloid (Aβ) on PSCI is uncertain. The proposed study will investigate amyloid pathology in participants with PSCI and how differently their cognition progress according to the amyloid pathology. Methods: This multicenter study was designed to be prospective and observational based on a projected cohort size of 196 participants with either newly developed cognitive impairment, or rapidly aggravated CI, within 3 months after acute cerebral infarction. They will undergo 18 F-flutemetamol positron emission tomography at baseline and will be categorized as either amyloid-positive (A+) or amyloid-negative (A−) by visual rating. The primary outcome measures will be based on Korean Mini-Mental State Examination changes (baseline to 12 months) between the A+ and A− groups. The secondary outcome measures will be the dementia-conversion rate and changes in the Korean version of the Montreal Cognitive Assessment (baseline to 12 months) between the A+ and A− groups. Conclusions: This study will provide a broadened perspective on the impact of Aβ on the cause and outcomes of PSCI in clinical practice. Identifying amyloid pathology in patients with PSCI will help select patients who need more focused treatments such as acetylcholinesterase inhibitors Trial registration: Clinical Research Information Service identifier: KCT0005086